» Articles » PMID: 11244579

Human Papillomavirus DNA in Plasma of Patients with Cervical Cancer

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2001 Mar 13
PMID 11244579
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Human papillomavirus (HPV) is a crucial etiological factor for cervical cancer (CC) development. From a diagnostic view-point, the consistent presence of HPV in CC allows the viral DNA to be used as a genetic marker. The aims of this study were to evaluate the presence, physical status and clinical significant of HPV DNA in circulation of CC patients.

Results: Whereas 6 out of 50 (12%) HPV positive CC patients revealed plasma HPV DNA, it was detected in none of 20 normal controls or 13 HPV negative CC cases. The plasma DNA exhibited an HPV type identical to the HPV in the primary tumors and the DNA from both sources was integrated into host genome. Interestingly, several findings suggested an association between plasma HPV DNA and metastasis. First, three of the HPV DNA positive cases were CC patients with clinical stage IVB or recurrence with distance metastases (P = 0.001, RR = 15.67). Second, the amount of plasma HPV DNA from metastatic patients to be three times more than three other patients without metastases. Finally, the later cases had tendency to develop recurrence distant metastases within one year after complete treatment when compared with other HPV associated CC patients with the same stage but without the present of plasma HPV DNA.

Conclusions: The plasma HPV DNA originated from the CC, was associated with metastasis and could be used as a marker representing the circulating free CC DNA.

Citing Articles

The clinical utility of circulating human papillomavirus across squamous cell carcinomas.

Spindler K, Jakobsen A, Eriksen J, Fokdal L, Nordsmark M, Thorsen L Acta Oncol. 2025; 64():1-12.

PMID: 39748655 PMC: 11711493. DOI: 10.2340/1651-226X.2025.41288.


Comparing the Diagnostic Performance of Quantitative PCR, Digital Droplet PCR, and Next-Generation Sequencing Liquid Biopsies for Human Papillomavirus-Associated Cancers.

Naegele S, Ruiz-Torres D, Zhao Y, Goss D, Faden D J Mol Diagn. 2023; 26(3):179-190.

PMID: 38103593 PMC: 10918646. DOI: 10.1016/j.jmoldx.2023.11.007.


Circulating cell-free HPV DNA is a strong marker for disease severity in cervical cancer.

Bonlokke S, Steiniche T, Sorensen B, Nyvang G, Lindegaard J, Blaakaer J Mol Oncol. 2023; 18(5):1231-1244.

PMID: 37853962 PMC: 11076984. DOI: 10.1002/1878-0261.13538.


Circulating HPV DNA as a Biomarker for Pre-Invasive and Early Invasive Cervical Cancer: A Feasibility Study.

Bryan S, Lee J, Gunu R, Jones A, Olaitan A, Rosenthal A Cancers (Basel). 2023; 15(9).

PMID: 37174056 PMC: 10177194. DOI: 10.3390/cancers15092590.


Circulating cervical cancer biomarkers potentially useful in medical attention (Review).

Ruiz Esparza Garrido R, Gutierrez M, Velazquez Flores M Mol Clin Oncol. 2023; 18(2):13.

PMID: 36761385 PMC: 9892968. DOI: 10.3892/mco.2023.2609.


References
1.
Cuzick J . Human papillomavirus testing for primary cervical cancer screening. JAMA. 2000; 283(1):108-9. DOI: 10.1001/jama.283.1.108. View

2.
Resnick R, Cornelissen M, Wright D, Eichinger G, Fox H, Ter Schegget J . Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst. 1990; 82(18):1477-84. DOI: 10.1093/jnci/82.18.1477. View

3.
Shotelersuk K, Khorprasert C, Sakdikul S, Pornthanakasem W, Voravud N, Mutirangura A . Epstein-Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res. 2000; 6(3):1046-51. View

4.
Sidransky D . Circulating DNA. What we know and what we need to learn. Ann N Y Acad Sci. 2000; 906:1-4. DOI: 10.1111/j.1749-6632.2000.tb06579.x. View

5.
Jen J, Wu L, Sidransky D . An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann N Y Acad Sci. 2000; 906:8-12. DOI: 10.1111/j.1749-6632.2000.tb06581.x. View